A putative role for histone deacetylase in the differentiation of human erythroid cells

International Journal of Oncology

Volumn 27, Issue 3, 2005, Pages 743-748

  Fujieda, Atsushi ^a   Katayama, Naoyuki ^a   Ohishi, Kohshi ^a   Yamamura, Kentaro ^a   Shibasaki, Tetsunori ^a   Sugimoto, Yuka ^a   Miyata, Eri ^a   Nishii, Kazuhiro ^a   Masuya, Masahiro ^b   Ueda, Hirotsugu ^c   Nakajima, Hidenori ^c   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

^c Fermentation Research Laboratories   (Japan)

Author keywords

Differentiation; Erythroid cells; Histone deacetylase; Inhibitor

Indexed keywords

CD36 ANTIGEN; CD45 ANTIGEN; DEPSIPEPTIDE; ERYTHROPOIETIN; FR 901228; GLYCOPHORIN; HISTONE; HISTONE DEACETYLASE;

ACETYLATION; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; ERYTHROID CELL; FLOW CYTOMETRY; HUMAN; METABOLISM; PHYSIOLOGY; TIME;

ACETYLATION; ANTIGENS, CD36; ANTIGENS, CD45; CELL DIFFERENTIATION; CELL PROLIFERATION; DEPSIPEPTIDES; ERYTHROID CELLS; ERYTHROPOIETIN; FLOW CYTOMETRY; GLYCOPHORIN; HISTONE DEACETYLASES; HISTONES; HUMANS; TIME FACTORS;

EID: 24344466361     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Felsenfeld G and Groudine M: Controlling the double helix. Nature 421: 448-453, 2003.
2. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
3. Eberharter A and Becker PB: Histone acetylation: a switch between repressive and permissive chromatin. EMBO Rep 3: 224-229, 2002.
4. Gregory PD, Wagner K and Horz W: Histone acetylation and chromatin remodeling. Exp Cell Res 265: 195-202, 2001.
5. Blau HM: Differentiation requires continuous active control. Annu Rev Biochem 61: 1213-1230, 1992.
6. Ogawa M: Differentiation and proliferation of hematopoietic stem cells. Blood 81: 2844-2853, 1993.
7. Zhu J and Emerson SG: Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 21: 3295-3313, 2002.
8. Hu M, Krause D, Greaves M, Sharkis S, Dexter M, Heyworth C and Enver T: Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 11: 774-785, 1997.
9. Akashi K, He X, Chen J, Iwasaki H, Niu C, Steenhard B, Zhang J, Haug J and Li L: Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood 101: 383-390, 2003.
10. Georgopoulos K: Haematopoietic cell-fate decisions, chromatin regulation and Ikaros. Nat Rev Immunol 2: 162-174, 2002.
11. Avni O and Rao A: T cell differentiation: a mechanistic view. Curr Opin Immunol 12: 654-659, 2000.
12. Akashi K, Traver D, Miyamoto T and Weissman IL: A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193-197, 2000.
13. Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, Crossley M and Orkin SH: FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocyte differentiation. Cell 90: 109-119, 1997.
14. Tsang AP, Fujiwara Y, Hom DB and Orkin SH: Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev 12: 1176-1188,1998.
15. Bottardi S, Aumont A, Grosveld F and Milot E: Developmental stage-specific epigenetic control of human ß-globin gene expression is potentiated in hematopoietic progenitor cells prior to their transcriptional activation. Blood 102: 3989-3997, 2003.
16. Miyata Y, Towatari M, Maeda T, Ozawa Y and Saito H: Histone acetylation induced by granulocyte colony stimulating factor in a MAP kinase-dependent manner. Biochem Biophys Res Commun 283: 655-660, 2001.
17. Fields PE, Kim ST and Flavell RA: Changes in histone acetylation at the IL-4 and IFN-y loci accompany Thl/Th2 differentiation. J Immunol 169: 647-650, 2002.
18. Minucci S, Nervi C, Lo Coco F and Pelicci PG: Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20: 3110-3115, 2001.
19. Warrell RP Jr, He L-Z, Richon V, Calleja E and Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998.
20. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T and Okuhara M: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968: I. taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 47: 301-310, 1994.
21. Nakajima H, Kim YB, Terano H, Yoshida M and Horinouchi S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241: 126-133,1998.
22. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M and Horinouchi S: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921, 2002.
23. Araki H, Katayama N, Yamashita Y, Mano H, Fujieda A, Usui E, Mitani H, Ohishi K, Nishii K, Masuya M, Minami N, Nobori T and Shiku H: Reprogramming of human postmitotic neutrophils into macrophages by growth factors. Blood 103: 2973-2980, 2004.
24. Amin HM, Saeed S and Alkan S: Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with f(15;17). Br J Haematol 115:287-297,2001.
25. Freyssinier JM, Lecoq-Lafon C, Amsellem S, Picard F, Ducrocq R, Mayeux P, Lacombe C and Fichelson S: Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol 106: 912-922, 1999.
26. + erythroid progenitors: temporal changes in gene and protein expression. Exp Hematol 31: 760-769, 2003.
27. Loken MR, Shah VO, Dattilio KL and Civin CI: Flow cytometric analysis of human bone marrow: I. normal erythroid development. Blood 69: 255-263, 1987.
28. Ogryzko VV, Schiltz RL, Russanova V, Howard BH and Nakatani Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959, 1996.
29. Orkin SH: GATA-binding transcription factors in hematopoietic cells. Blood 80: 575-581, 1992.
30. Boyes J, Byfield P, Nakatani Y and Ogryzko V: Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396: 594-598, 1998.
31. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
32. Johnstone RW and Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18,2003.
33. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP and Bates SE: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728,2002.
34. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ and Hawkins MJ: A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2: 325-332, 2002.
35. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Skienar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK and Grever MR: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105: 959-967, 2005.
36. Milhem M, Mahmud N, Lavelle D, Araki H, De Simone J, Saunthararajah Y and Hoffman R: Modification of hematopoietic stem cell fate by 5-aza- 2'deoxycytidine and trichostatin A. Blood 103:4102-4110,2004.
37. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005.